

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	I13V ^{100%} _{cons=1,362} • E33D ^{100%} _{cons=1,328} • M36I ^{100%} _{cons=1,328} • R41K ^{99%} _{cons=1,024} • R57K ^{99%} _{cons=2,230} • H69K ^{99%} _{cons=2,057} • L89M ^{100%} _{cons=2,623}	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
Mutation scoring: PR		HIVDB 9.5.1 (2023-11-05)

Drug resistance interpretation: RT

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

None

None

E6D 99%
cons=2,336 • V8I 100%
cons=1,232 • E28ED 0.42%
0.14%
cons=2,674 • V35T 99%
cons=2,307 • K49R 99%
cons=1,873 • V60I 100%
cons=1,837 • K64KR 0.19%
0.12%
cons=1,368 • D123N 100%
cons=2,361 • R125RK 0.10%
0.10%
cons=2,047 • I135T 99%
cons=2,230 • I142V 99%
cons=2,236 • K173S 99%
cons=2,362 • Q174K 100%
cons=1,362 • D177E 100%
cons=2,367 • V179I 100%
cons=2,362 • T200A 100%
cons=1,862 • I202V 100%
cons=1,756 • Q207G 100%
cons=1,836 • R211K 99%
cons=1,825 • G231GE 0.42%
0.14%
cons=546 • V245K 100%
cons=1,23 • D250E 99%
cons=117 • S251SN 0.57%
0.47%
cons=117 • A354S 100%
cons=62

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

zidovudine (AZT)

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

tenofovir (TDF)

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

Susceptible

Susceptible

Susceptible

Susceptible

RT comments

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for NRTI.	
No drug resistance mutations were found for NNRTI.	

Drug resistance interpretation: IN		HIVDB 9.5.1 (2023-11-05)
INSTI Major Mutations:	None	
INSTI Accessory Mutations:	None	
IN Other Mutations:	K14R ^{100%} _{cons=132} • A21T ^{100%} _{cons=138} • I72V ^{100%} _{cons=157} • T112V ^{100%} _{cons=157} • I113V ^{100%} _{cons=157} • T124A ^{99%} _{cons=126} • T125A ^{100%} _{cons=126} • V126F ^{100%} _{cons=126} • G134S ^{100%} _{cons=132} • I135V ^{100%} _{cons=132} • D167E ^{100%} _{cons=140} • V201I ^{100%} _{cons=229} • K211R ^{100%} _{cons=237} • K219N ^{100%} _{cons=236} • N222K ^{100%} _{cons=236} • L234I ^{100%} _{cons=229} • S283G ^{100%} _{cons=230}	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC)	Susceptible	
cabotegravir (CAB)	Susceptible	
dolutegravir (DTG)	Susceptible	
elvitegravir (EVG)	Susceptible	
raltegravir (RAL)	Susceptible	
Mutation scoring: IN		HIVDB 9.5.1 (2023-11-05)